AnaMar Medical AB: AnaMar Medical Raises SEK 75 Million in New Financing

STOCKHOLM, Sweden--(Business Wire)--
The Swedish biotech company AnaMar Medical raises SEK 75 millon in
a rights issue to finance continued development of its projects in
chronic joint diseases. In a first step, the funds will finance a
phase I study of a drug candidate developed for rheumatoid arthritis.

"We are happy to have successfully secured SEK 75 million in new
financing in the current financial climate. It's an acknowledgement
that our principal owner shares our confidence in our projects. With
this financing in place, we can take the first step into the clinic,"
says AnaMar's CEO Owe Garlin. "First in line is a compound that is
being developed for rheumatoid arthritis for which we will submit a
Clinical Trials Application early next year. Our next project is also
approaching studies in man."

The funds are provided through a rights issue guaranteed by
AnaMar's principal owner Koncentra Holding AB. All shareholders are
invited to participate in the rights issue.

The drug candidate that is currently being prepared for clinical
studies is developed in the project AM240 MCR and is an orally
bioactive small molecule compound that in preclinical studies has been
shown to suppress inflammation and cartilage destruction in disease
models for rheumatoid arthritis. The compound has also shown effect on
pain.

The other project, AM260 TASS, is a compound that targets a
receptor system which is known to be involved in the immunomodulation
process. The main indication is treatment of rheumatoid arthritis.
There are currently no drugs on the market using the target receptor
for the chosen indication.

AnaMar's focus is the identification and treatment of chronic
joint disease, in particular rheumatoid arthritis. The company was
founded in 1998 to commercialize research by the professors Dick
Heinegard and Tore Saxne at the University in Lund, Sweden. Today,
AnaMar has a broad portfolio of five drug development projects and
three biomarkers, originating from academic institutions and selected
partners.

AnaMar's largest owners are Koncentra Holding AB and LinkMed AB.

This information was brought to you by Cision
http://www.cisionwire.com

AnaMar Medical AB
Owe Garlin, CEO
+ 46 31 732 41 42

Copyright Business Wire 2008